フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
Mithra and Searchlight Pharma Announce Donesta® Licensing Agreement for Canada Mithra to receive up to...
Notice of Adjustment of the Conversion Price of Mithra's EUR 125,000,000 Senior Unsecured Convertible Bonds due 2025 Notice of...
Notice of Adjustment of the Conversion Price of Mithra's EUR 125,000,000 Senior Unsecured Convertible Bonds due 2025 (ISIN: BE6325746855...
Mithra Announces Information on the Total Number of Voting Rights (Denominator) Mithra Announces Information on the Total Number of Voting...
Mithra has access to the new EUR 12.5 million tranche of the Highbridge/Whitebox loan facility Mithra has access to the new EUR 12.5...
Mithra Announces New Positive Preclinical Data from CSF-1R Inhibitor Program Mithra Announces New Positive Preclinical Data from CSF-1R...
Mithra - Publication of a transparency notification received from Scorpiaux BV Publication of a transparency notification received from...
Mithra Appoints Experienced Life Sciences Executive Christian Homsy* as Chairman Inge Beernaert appointed President of the Compensation and...
Mithra’s General Meeting Of Shareholders Approves the Renewal of its Board of Directors Mithra’s General Meeting Of Shareholders Approves...
Mithra’s General Meeting Of Shareholders Approves the Renewal of its Board of Directors Liege, Belgium, 25 MAY 2023 – 5:45 CEST – Mithra...
Letter to Shareholders and Corporate Update Access to EUR15 million under amended dealDonesta® U.S...
Mithra Pharmaceuticals - Payment of the interests of the Highbridge/Whitebox loans Information on the total number of voting rights...
Mithra Announces Completion of Recruitment in Pediatric Study of Estelle in Adolescent Patients Mithra Announces Completion of Recruitment...
Mithra and the University of Liège Secure Proof-of-Concept for Novel Manufacturing Process of Estetrol Collaboration demonstrates Mithra’s...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約